PUBLICACIONS 2018
Lopez-Anglada L, Cueto-Felgueroso C, Rosiñol L, Oriol A, Teruel AI, Lopez de la Guia A, Bengoechea E, Palomera L, de Arriba F, Hernandez JM, Granell M, Peñalver FJ, Garcia-Sanz R, Besalduch J, Gonzalez Y, Martinez RB, Hernandez MT, Gutierrez NC, Puerta P, Valeri A, Paiva B, Blade J, Mateos MV, San Miguel J, Lahuerta JJ, Martinez-Lopez J; GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Group. Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials. PLoS One. 2018 Sep 7;13(9)
Rodríguez-Otero P, Mateos MV, Martínez-López J, Martín-Calvo N, Hernández MT, Ocio EM, Rosiñol L, Martínez R, Teruel AI, Gutiérrez NC, Bargay J, Bengoechea E, González Y, de Oteyza JP, Gironella M, Encinas C, Martín J, Cabrera C, Palomera L, de Arriba F, Cedena MT, Paiva B, Puig N, Oriol A, Bladé J, Lahuerta JJ, San Miguel JF. Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role. Leukemia. 2018 Nov;32(11):2427-2434
Gatterman N, Coll R, Jacobasch L, Allameddine A, Amon A, DeBonnett L, Bruederle A, Jin J; KALLISTO study investigators. Effect of deferasirox + erythropoietin vs erythropoietin on erythroid response in Low/Int-1-risc MDS patients: Results of the phase II KALLISTO trial. European Journal of Heamatology. 2018 May 19, vol.101, issue 2, pp 208-215
Palomo L, Malinverni R, Cabezón M, Xicoy B, Arnan M, Coll R, Pomares H, García O, Fuster-Tormo F, Grau J, Feliu E, Solé F, Bushbeck M, Zamora L. DNA methylation profile in chronic myelomonocytic leukemia associates with distinct clinical, biological and genetic features. Epigenetics. 2018;13(1):8-18
Hernández-Boluda JC, Pereira A, Pastor-Galán I, Alvarez-Larrán A, Savchuk A, Puerta JM, Sánchez-Pina JM, Collado R, Díaz-González A, Angona A, Sagüés M, García-Gutiérrez V, Boqué C, Osorio S, Vallansot R, Palomera L, Mendizábal A, Casado LF, Pérez-Encinas M, Pérez-López R, Ferrer-Marín F, Sánchez-Guijo F, García C, Heras NL, López-Lorenzo JL, Cervantes F, Steegmann JL; Grupo Español de Leucemia Mieloide Crónica (GELMC). Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients. Blood Cancer J. 2018 Dec 2;8(10):91.
Solans M, Fàbrega A, Morea D, Auñon-Sanz C, Granada I, Roncero JM, Blanco A, Kelleher N, Buch J, Saez M, Marcos-Gragera R. Population-based incidence of lymphoid neoplasms: Twenty years of epidemiological data in the Girona province, Spain. Cancer Epidemiol. 2019 Feb;58:8-11.
Guillem V, Calabuig M, Brunet S, Esteve J, Escoda L, Gallardo D, Ribera JM, Queipo de Llano MP, Arnan M, Pedro C, Amigo ML, Martí-Tutusaus JM, García-Guiñón A, Bargay J, Sampol A, Salamero O, Font L, Talarn C, Hoyos M, Díaz-Beyá M, Garrido A, Navarro B, Nomdédeu J, Sierra J, Tormo M. Bone marrow VEGFC expression is associated with multilineage dysplasia and several prognostic markers in adult acute myeloid leukemia, but not with survival. Leuk Lymphoma. 2018 Oct;59(10):2383-2393.
Solans M, Osca-Gelis G, Comas R, Roncero JM, Gallardo D, Marcos-Gragera R, Saez M. Challenges in assessing the real incidence of chronic lymphocytic leukemia: 16 years of epidemiological data from the province of Girona, Spain. Cancer Causes Control. 2018 Mar;29(3):379-382.
Santos N, Rodríguez-Romanos R, de la Cámara R, Brunet S, Nieto JB, Buño I, Martínez C, Jiménez-Velasco A, Vallejo C, González M, Solano C, Ferrá C, Sampol A, Pérez-Simón JA, López-Jiménez J, Díez JL, Gallardo D. PD-1 genotype of the donor is associated with acute graft-versus-host disease after HLA-identical sibling donor stem cell transplantation. Ann Hematol. 2018 Nov;97(11):2217-2224.
Martínez-Laperche C, Buces E, Aguilera-Morillo MC, Picornell A, González-Rivera M, Lillo R, Santos N, Martín-Antonio B, Guillem V, Nieto JB, González M, de la Cámara R, Brunet S, Jiménez-Velasco A, Espigado I, Vallejo C, Sampol A, Bellón JM, Serrano D, Kwon M, Gayoso J, Balsalobre P, Urbano-Izpizua Á, Solano C, Gallardo D, Díez-Martín JL, Romo J, Buño I. A novel predictive approach for GVHD after allogeneic SCT based on clinical variables and cytokine gene polymorphisms. Blood Adv. 2018 Jul 24;2(14):1719-1737.
PUBLICACIONS 2019
O'Connor OA, Özcan M, Jacobsen ED, Roncero JM, Trotman J, Demeter J, Masszi T, Pereira J, Ramchandren R, Beaven A, Caballero D, Horwitz SM, Lennard A, Turgut M, Hamerschlak N, d'Amore FA, Foss F, Kim WS, Leonard JP, Zinzani PL, Chiattone CS, Hsi ED, Trümper L, Liu H, Sheldon-Waniga E, Ullmann CD, Venkatakrishnan K, Leonard EJ, Shustov AR; Lumiere Study Investigators. Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma. J Clin Oncol. 2019 Mar 10;37(8):613-623. doi: 10.1200/JCO.18.00899. Epub 2019 Feb 1. PubMed PMID: 30707661; PubMed Central PMCID: PMC6494247.
Solans M, Fàbrega A, Morea D, Auñon-Sanz C, Granada I, Roncero JM, Blanco A, Kelleher N, Buch J, Saez M, Marcos-Gragera R. Population-based incidence of lymphoid neoplasms: Twenty years of epidemiological data in the Girona province, Spain. Cancer Epidemiol. 2019 Feb;58:8-11. doi: 10.1016/j.canep.2018.11.001. Epub
2018 Nov 10. PubMed PMID: 30423540.
Gassiot S, González Y, Morgades M, Motlló C, Clapés V, Maluquer C, Ibarra G, Abril L, Ribera JM, Oriol A. Response to First Cycle Is the Major Predictor of Long-Term Response to Lenalidomide and Dexamethasone Therapy in Relapsed and Refractory Multiple Myeloma: Can We Spare Patients the Toxicity and Costs of Additional Agents? Clin Lymphoma Myeloma Leuk. 2019 Sep;19(9):585-592.e1. doi: 10.1016/j.clml.2019.05.020. Epub 2019 Jun 5. PubMed PMID: 31255588.
Rodríguez-Otero P, Mateos MV, Martínez-López J, Martín-Calvo N, Hernández MT, Ocio EM, Rosiñol L, Martínez R, Teruel AI, Gutiérrez NC, Bargay J, Bengoechea E, González Y, de Oteyza JP, Gironella M, Encinas C, Martín J, Cabrera C, Palomera L, de Arriba F, Cedena MT, Paiva B, Puig N, Oriol A, Bladé J, Lahuerta JJ, Miguel
JFS. Correction: Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role. Leukemia. 2019 Apr;33(4):1056. doi: 10.1038/s41375-019-0408-x. PubMed PMID: 30846864.
Acha P, Xandri M, Fuster-Tormo F, Palomo L, Xicoy B, Cabezón M, Marcé S, Granada I, Vela D, Sagüés M, Boque C, Plensa E, Pineda A, Feliu E, Solé F, Zamora L. Diagnostic and prognostic contribution of targeted NGS in patients with triple-negative myeloproliferative neoplasms. Am J Hematol. 2019 Oct;94(10):E264-E267. doi: 10.1002/ajh.25580. Epub 2019 Aug 6. PubMed PMID: 31321810.
Cruz D, Costa P, Sagüés M. Meningeal cryptococcosis in a patient with angioimmunoblastic lymphoma treated with alemtuzumab. Med Clin (Barc). 2019 Feb 15;152(4):e19-e20. doi: 10.1016/j.medcli.2018.05.030. Epub 2018 Jul 9. PubMed PMID: 30001898.
Genescà E, Morgades M, Montesinos P, Barba P, Gil C, Guàrdia R, Moreno MJ, Martínez-Carballeira D, García-Cadenas I, Vives S, Ribera J, González-Campos J, González-Gil C, Zamora L, Ramírez JL, Díaz-Beya M, Mercadal S, Artola MT, Cladera A, Tormo M, Bermúdez A, Vall-Llovera F, Martínez P, Amigo ML, Monsalvo S, Novo A,
Cervera M, García-Guiñon A, Juncà J, Ciudad J, Orfao A, Ribera JM. Unique clinico-biological, genetic and prognostic features of adult early T cell precursor acute lymphoblastic leukemia. Haematologica. 2019 Sep 19. pii: haematol.2019.225078. doi: 10.3324/haematol.2019.225078. [Epub ahead of print] PubMed PMID: 31537688.
Ribera J, Zamora L, Morgades M, Vives S, Granada I, Montesinos P, Gómez-Seguí I, Mercadal S, Guàrdia R, Nomdedeu J, Pratcorona M, Tormo M, Martínez-Lopez J, Hernández-Rivas JM, Ciudad J, Orfao A, González-Campos J, Barba P, Escoda L, Esteve J, Genescà E, Solé F, Feliu E, Ribera JM; Spanish PETHEMA Group; Spanish
Society of Hematology. Molecular profiling refines minimal residual disease-based prognostic assessment in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2019 Nov;58(11):815-819. doi: 10.1002/gcc.22788. Epub 2019 Aug 7. PubMed PMID:
31340073.
Barba P, Morgades M, Montesinos P, Gil C, Fox ML, Ciudad J, Moreno MJ, González-Campos J, Genescà E, Martínez-Carballeira D, Martino R, Vives S, Guardia R, Mercadal S, Artola MT, Cladera A, Tormo M, Esteve J, Bergua J, Vall-Llovera F, Ribera J, Martínez-Sanchez P, Amigo ML, Bermúdez A, Calbacho M, Hernández-Rivas
JM, Feliu E, Orfao A, Ribera JM. Increased survival due to lower toxicity for high-risk T-cell acute lymphoblastic leukemia patients in two consecutive pediatric-inspired PETHEMA trials. Eur J Haematol. 2019 Jan;102(1):79-86. doi: 10.1111/ejh.13178. Epub 2018 Nov 22. PubMed PMID: 30267597.
Sitges M, Vives S, Ribera JM. Blastic plasmacytoid dendritic cell neoplasm. A study of three cases. Med Clin (Barc). 2019 Jul 23. pii: S0025-7753(19)30405-1. doi: 10.1016/j.medcli.2019.04.029. [Epub ahead of print] English, Spanish. PubMed PMID: 31350059.
Publicacions 2020
Alvarez-Larrán A, Angona A, Andrade-Campos M, Soledad Noya M, Teresa Gómez-Casares M, Cuevas B, Caballero G, García-Hernández C, García-Gutiérrez V, Palomino A, Ferrer-Marín F, Isabel Mata-Vázquez M, Moretó A, Magro E, Murillo I, Manuel Alonso-Domínguez J, María Guerra J, Guerrero L, María Raya J, Pérez-Encinas M, Carreño-Tarragona G, Fox L, Pastor-Galán I, Bellosillo B, Hernández-Boluda JC; MPN Spanish Group (GEMFIN). Cytoreductive treatment in patients with CALR-mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish Registry of Essential Thrombocythaemia. Br J Haematol. 2020 Aug 3. doi: 10.1111/bjh.16988.
Bataller A, Oñate G, Diaz-Beyá M, Guijarro F, Garrido A, Vives S, Tormo M, Arnan M, Salamero O, Sampol A, Coll R, Vall-Llovera F, Oliver-Caldés A, López-Guerra M, Pratcorona M, Zamora L, Villamon E, Roué G, Blanco A, Nomdedeu JF, Colomer D, Brunet S, Sierra J, Esteve J; Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias (CETLAM). Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease. Br J Haematol. 2020 Oct;191(1):52-61. doi: 10.1111/bjh.16857.
De Stefano V, Ghirardi A, Masciulli A, Carobbio A, Palandri F, Vianelli N, Rossi E, Betti S, Di Veroli A, Iurlo A, Cattaneo D, Finazzi G, Bonifacio M, Scaffidi L, Patriarca A, Rumi E, Casetti IC, Stephenson C, Guglielmelli P, Elli EM, Palova M, Rapezzi D, Erez D, Gomez M, Wille K, Perez-Encinas M, Lunghi F, Angona A, Fox ML, Beggiato E, Benevolo G, Carli G, Cacciola R, McMullin MF, Tieghi A, Recasens V, Isfort S, Marchetti M, Griesshammer M, Alvarez-Larran A, Vannucchi AM, Rambaldi A, Barbui T. Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study. Blood. 2020 Jan 30;135(5):381-386. doi: 10.1182/blood.2019002614.
Díaz-Santa J, Rodríguez-Romanos R, Osca G, Pratcorona M, Garrido A, Coll R, Moret C, Escoda L, Tormo M, Heras I, Arnan M, Vives S, Salamero O, Lloveras N, Bargay J, Sampol A, Cruz D, Garcia A, Quiñones T, Esteve J, Sierra J, Gallardo D; on the behalf of CETLAM Group. UGT1A1 genotype influences clinical outcome in patients with intermediate-risk acute myeloid leukemia treated with cytarabine-based chemotherapy. Leukemia. 2020 Nov;34(11):2925-2933. doi: 10.1038/s41375-020-0784-2.
Garcia-Gisbert N, Camacho L, Fernández-Ibarrondo L, Fernández-Rodriguez C, Longarón R, Gibert J, Angona A, Andrade-Campos M, Salar A, Besses C, Bellosillo B. Analysis of saliva samples and cluster of differentiation 3 (CD3)+ lymphocytes as a source of germline DNA in myeloproliferative neoplasms. Br J Haematol. 2020 Jun;189(5):e204-e207. doi: 10.1111/bjh.16624.
Hyvärinen K, Koskela S, Niittyvuopio R, Nihtinen A, Volin L, Salmenniemi U, Putkonen M, Buño I, Gallardo D, Itälä-Remes M, Partanen J, Ritari J. Meta-Analysis of Genome-Wide Association and Gene Expression Studies Implicates Donor T Cell Function and Cytokine Pathways in Acute GvHD. Front Immunol. 2020 Feb 3;11:19. doi: 10.3389/fimmu.2020.00019.
Marchetti M, Ghirardi A, Masciulli A, Carobbio A, Palandri F, Vianelli N, Rossi E, Betti S, Di Veroli A, Iurlo A, Cattaneo D, Finazzi G, Bonifacio M, Scaffidi L, Patriarca A, Rumi E, Casetti IC, Stephenson C, Guglielmelli P, Elli EM, Palova M, Rapezzi D, Erez D, Gomez M, Wille K, Perez-Encinas M, Lunghi F, Angona A, Fox ML, Beggiato E, Benevolo G, Carli G, Cacciola R, McMullin MF, Tieghi A, Recasens V, Isfort S, Pane F, De Stefano V, Griesshammer M, Alvarez-Larran A, Vannucchi AM, Rambaldi A, Barbui T. Second cancers in MPN: Survival analysis from an international study. Am J Hematol. 2020 Mar;95(3):295-301. doi: 10.1002/ajh.25700.
Martínez C, Carpio C, Heras I, Ríos-Herranz E, Buch J, Gutierrez A, Romero S, Zeberio I, García-García I, Rodriguez-Izquierdo A, Alonso R, Bargay J, Barrenetxea C, Domingo-Doménech E, de Haro ME, Palomera L, García-Sanz R; Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO). Potential Survival Benefit for Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation after Nivolumab Therapy for Relapse/Refractory Hodgkin Lymphoma: Real-Life Experience in Spain. Biol Blood Marrow Transplant. 2020 Aug;26(8):1534-1542. doi: 10.1016/j.bbmt.2020.02.003.
Parody R, Sánchez-Ortega I, Ferrá C, Guardia R, Talarn C, Encuentra M, Fort E, López D, Morgades M, Alonso E, Ortega S, Sarrá J, Gallardo D, Ribera JM, Sureda A. Mobilization of Hematopoietic Stem Cells into Peripheral Blood for Autologous Transplantation Seems Less Efficacious in Poor Mobilizers with the Use of a Biosimilar of Filgrastim and Plerixafor: A Retrospective Comparative Analysis. Oncol Ther. 2020 Dec;8(2):311-324. doi: 10.1007/s40487-020-00115-3.
Pastor-Galán I, Hernández-Boluda JC, Correa JG, Alvarez-Larrán A, Ferrer-Marín F, Raya JM, Ayala R, Velez P, Pérez-Encinas M, Estrada N, García-Gutiérrez V, Fox ML, Payer A, Kerguelen A, Cuevas B, Durán MA, Ramírez MJ, Gómez-Casares MT, Mata-Vázquez MI, Mora E, Martínez-Valverde C, Arbelo E, Angona A, Magro E, Antelo ML, Somolinos N, Cervantes F; en representación del Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN). Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of Myelofibrosis. Med Clin (Barc). 2020 Aug 28;155(4):152-158. doi: 10.1016/j.medcli.2019.11.007.
Piñana JL, Martino R, García-García I, Parody R, Morales MD, Benzo G, Gómez-Catalan I, Coll R, De La Fuente I, Luna A, Merchán B, Chinea A, de Miguel D, Serrano A, Pérez C, Diaz C, Lopez JL, Saez AJ, Bailen R, Zudaire T, Martínez D, Jurado M, Calbacho M, Vázquez L, Garcia-Cadenas I, Fox L, Pimentel AI, Bautista G, Nieto A, Fernandez P, Vallejo JC, Solano C, Valero M, Espigado I, Saldaña R, Sisinni L, Ribera JM, Jimenez MJ, Trabazo M, Gonzalez-Vicent M, Fernández N, Talarn C, Montoya MC, Cedillo A, Sureda A; Infectious Complications Subcommittee of the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH). Risk factors and outcome of COVID-19 in patients with hematological malignancies. Exp Hematol Oncol. 2020 Aug 25;9:21. doi: 10.1186/s40164-020-00177-z.
Ribera JM, Morgades M, Ciudad J, Montesinos P, Esteve J, Genesca E, Barba P, Ribera J, García Cadenas I, Moreno MJ, Martínez-Carballeira D, Torrent A, Martínez-Sánchez P, Monsalvo S, Gil C, Tormo M, Artola MT, Cervera M, González-Campos J, Rodríguez-Medina C, Bermúdez A, Novo A, Soria B, Coll R, Amigo ML, López A, Fernández Martín R, Serrano J, Mercadal S, Cladera A, Giménez-Conca AD, Peñarrubia MJ, Abella E, Vall-Llovera F, Hernández-Rivas JM, Garcia A, Bergua Burgues JM, de Rueda B, Sánchez-Sánchez MJ, Serrano A, Calbacho M, Alonso Vence N, Méndez-Sánchez JÁ, García-Boyero R, Olivares M, Barrena S, Zamora L, Granada I, Lhermitte L, Feliu E, Orfao A. Chemotherapy or Allogeneic Transplantation in High-Risk Philadelphia Chromosome-Negative Adult Lymphoblastic Leukemia. Blood. 2020 Nov 4:blood.2020007311. doi: 10.1182/blood.2020007311.
Ribera JM, Morgades M, Montesinos P, Tormo M, Martínez-Carballeira D, González-Campos J, Gil C, Barba P, García-Boyero R, Coll R, Pedreño M, Ribera J, Mercadal S, Vives S, Novo A, Genescà E, Hernández-Rivas JM, Bergua J, Amigo ML, Vall-Llovera F, Martínez-Sánchez P, Calbacho M, García-Cadenas I, Garcia-Guiñon A, Sánchez-Sánchez MJ, Cervera M, Feliu E, Orfao A; PETHEMA Group, Spanish Society of Hematology. A pediatric regimen for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: Results of the ALLRE08 PETHEMA trial. Cancer Med. 2020 Apr;9(7):2317-2329. doi: 10.1002/cam4.2814.
Sánchez R, Ribera J, Morgades M, Ayala R, Onecha E, Ruiz-Heredia Y, Juárez-Rufián A, de Nicolás R, Sánchez-Pina J, Vives S, Zamora L, Mercadal S, Coll R, Cervera M, García O, Ribera JM, Martínez-López J. A novel targeted RNA-Seq panel identifies a subset of adult patients with acute lymphoblastic leukemia with BCR-ABL1-like characteristics. Blood Cancer J. 2020 Apr 24;10(4):43. doi: 10.1038/s41408-020-0308-3.
Sitges M, Boluda B, Garrido A, Morgades M, Granada I, Barragan E, Arnan M, Serrano J, Tormo M, Miguel Bergua J, Colorado M, Salamero O, Esteve J, Benavente C, Pérez-Encinas M, Coll R, Martí-Tutusaus JM, Brunet S, Sierra J, Ángel Sanz M, Montesinos P, Ribera JM, Vives S; PETHEMA, CETLAM cooperative groups. Acute myeloid leukemia with inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2): Study of 61 patients treated with intensive protocols. Eur J Haematol. 2020 Aug;105(2):138-147. doi: 10.1111/ejh.13417.
Sorigue M, Junca J, Ferra C, Marce S, Ruiz-Xivillé N, Pinyol L, Cabezon M, Espasa A, Dominguez D, Lopez-Viaplana L, Ruiz R, Buch J, Plensa E, Mostacedo SZ, Aranda J, Vergara S, Raya M, Granada I, Tapia G, Navarro JT, Beà S, Zamora L. FMOD expression in whole blood aids in distinguishing between chronic lymphocytic leukemia and other leukemic lymphoproliferative disorders. A pilot study. Cytometry B Clin Cytom. 2020 Sep;98(5):421-428. doi: 10.1002/cyto.b.21890.
Villavicencio A, Solans M, Auñon-Sanz C, Roncero JM, Marcos-Gragera R. Population-based survival of lymphoid neoplasms: Twenty years of epidemiological data in the Girona province, Spain. Cancer Epidemiol. 2020 Dec;69:101841. doi: 10.1016/j.canep.2020.101841.
Publicacions 2021
Acha P, Hoyos M, Pratcorona M, Fuster-Tormo F, Palomo L, Ortega E, Zamora L, Vives S, Granada I, Montoro J, Garcia A, Arnan M, Cervera M, Canet M, Gallardo D, Arenillas L, Esteve J, Bargay J, Salamero O, Motlló C, Ortín X, Sierra J, Solé F. Genetic characterization of acute myeloid leukemia patients with mutations in IDH1/2 genes. Leuk Res. 2021 Feb;101:106492. IF: 3.156.
Alvarez A, Angona A, Andrade M, Soledad M,Teresa Gómez M, Cuevas B, Caballero G, García C, García V, Palomino A, Ferrer F, Isabel Mata M, Moretó A, Magro E, Murillo I, Manuel Alonso J, María J, Guerrero L, María J, Pérez M, Carreño G, Fox L, Pastor I, Bellosillo B, Hernández JC, Spanish Group (GEMFIN) MPN. Cytoreductive treatment in patients with CALR-mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish Registry of Essential Thrombocythaemia. Br. J. Haematol. 2021. 192. (6):p. 988-996. IF: 6,998.
Barbui T, De Stefano V, Alvarez-Larran A, Iurlo A, Masciulli A, Carobbio A, Ghirardi A, Ferrari A, Cancelli V, Elli EM, Andrade-Campos MM, Kabat MG, Kiladjian JJ, Palandri F, Benevolo G, Garcia-Gutierrez V, Fox ML, Foncillas MA, Morcillo CM, Rumi E, Osorio S, Papadopoulos P, Bonifacio M, Cervantes KSQ, Serrano MS, Carreno-Tarragona G, Sobas MA, Lunghi F, Patriarca A, Elorza BN, Angona A, Mazo EM, Koschmieder S, Carli G, Cuevas B, Hernandez-Boluda JC, Abadia EL, Cirici BX, Guglielmelli P, Garrote M, Cattaneo D, Daffini R, Cavalca F, Bellosillo B, Benajiba L, Curto-Garcia N, Bellini M, Betti S, Harrison C, Rambaldi A, Vannucchi AM. Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19. Blood Cancer J. 2021 Feb 4;11(2):21. IF: 3.607.
Barbui T, Iurlo A, Masciulli A, Carobbio A, Ghirardi A, Rossi G, Harrison C, Alvarez-Larran A, Elli EM, Kiladjian JJ, Gasior Kabat M, Marin Sanchez A, Palandri F, Andrade-Campos MM, Vannucchi AM, Carreno-Tarragona G, Papadopoulos P, Quiroz Cervantes K, Angeles Foncillas M, Fox ML, Sagues Serrano M, Rumi E, Osorio S, Benevolo G, Patriarca A, Navas Elorza B, Garcia-Gutierrez V, Magro Mazo E, Lunghi F, Bonifacio M, De Stefano V, Hernandez-Boluda JC, Lopez Abadia E, Angona A, Xicoy Cirici B, Ruggeri M, Koschmieder S, Sobas MA, Cuevas B, Cattaneo D, Daffini R, Bellini M, Curto-Garcia N, Garrote M, Cavalca F, Benajiba L, Bellosillo B, Guglielmelli P, Borsani O, Betti S, Salmoiraghi S, Rambaldi A. Long-term follow-up of recovered MPN patients with COVID-19. Blood Cancer J. 2021 Jun 16;11(6):115. IF: 3.607.
Barbui T, Vannucchi AM, Alvarez A, Iurlo A, Masciulli A, Carobbio A, Ghirardi A, Ferrari A, Rossi G, Elli E, Andrade MM, Kabat MG, Kiladjian JJ, Palandri F, Benevolo G, Garcia V, Fox ML, Foncillas MA, Morcillo CM, Rumi E, Osorio S, Papadopoulos P, Bonifacio M, Cervantes KSQ, Serrano MS, Carreno G, Sobas MA, Lunghi F, Patriarca A, Elorza BN, Angona A, Mazo EM, Koschmieder S, Ruggeri M, Cuevas B, Hernandez JC, Abadia EL, Cirici BX, Guglielmelli P, Garrote M, Cattaneo D, Daffini R, Cavalca F, Bellosillo B, Benajiba L, Curto N, Bellini M, Betti S, De Stefano V, Harrison C, Rambaldi A. High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. Leukemia. 2021. 35. (2):p. 485-493. IF: 11,528.
Bataller A, Garrido A, Guijarro F, Oñate G, Diaz-Beya M, Arnan M, Tormo M, Vives S, Queipo DE Llano MP, Coll R, Gallardo D, Vall-Llovera F, Escoda L, García-Guiñon A, Salamero O, Sampol A, Merchan B, Bargay J, Castaño-Díez S, Esteban D, Oliver-Caldes A, Rivero A, Mozas P, López-Guerra M, Pratcorona M, Zamora L, Costa D, Rozman M, Nomdedeu JF, Colomer D, Brunet S, Sierra J, Esteve J. European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol. Blood Adv. 2021 Dec 15:bloodadvances.2021005585. IF: 6.799.
Cabezón M, Malinverni R, Bargay J, Xicoy B, Marcé S, Garrido A, Tormo M, Arenillas L, Coll R, Borras J, Jiménez MJ, Hoyos M, Valcárcel D, Escoda L, Vall F, Garcia A, Font LL, Rámila E, Buschbeck M, Zamora L, CETLAM G. Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival. Clin Epigenetics. 2021. 13. (1):p. 9-9. IF: 6,551.
Cejalvo MJ, Bustamante G, González E, Vázquez-Álvarez J, García R, Ramírez-Payer Á, Pérez-Persona E, Abella E, Garzón S, García A, Jarque I, González MS, Sampol A, Motlló C, Martí JM, Alcalá M, Duro R, González Y, Sastre JL, Sarrà J, Lostaunau G, López R, de la Rubia J. Treatment patterns and outcomes in real-world transplant-ineligible patients newly diagnosed with multiple myeloma. Ann Hematol. 2021 Jul;100(7):1769-1778. IF: 2.30.
Garcia-Gisbert N, Fernández-Ibarrondo L, Fernández-Rodríguez C, Gibert J, Andrade-Campos M, Arenillas L, Camacho L, Angona A, Longarón R, Salar A, Calvo X, Besses C, Bellosillo B. Circulating cell-free DNA improves the molecular characterisation of Ph-negative myeloproliferative neoplasms. Br J Haematol. 2021 Jan;192(2):300-309. IF: 6,998.
Garcia-Gutiérrez V, Luna A, Alonso-Dominguez JM, Estrada N, Boque C, Xicoy B, Giraldo P, Angona A, Alvarez-Larrán A, Sanchez-Guijo F, Ramírez MJ, Mora E, Vélez P, Rosell A, Colorado Araujo M, Cuevas B, Sagüés M, Cortes M, Encinas MP, Casado Montero LF, Moreno Vega M, Serrano L, Gomez V, Garcia-Hernandez C, Lakhwani S, Paz Coll A, de Paz R, Suarez-Varela S, Fernandez-Ruiz A, Perez Lopez R, Ortiz-Fernández A, Jiménez-Velasco A, Steegmann-Olmedillas JL, Hernández- Boluda JC. Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice. Blood Cancer J. 2021 Feb 9;11(2):16. IF: 3.607.
Genescà E, Morgades M, González-Gil C, Fuster-Tormo F, Haferlach C, Meggendorfer M, Montesinos P, Barba P, Gil C, Coll R, Moreno MJ, Martínez- Carballeira D, García-Cadenas I, Vives S, Ribera J, González-Campos J, Díaz-Beya M, Mercadal S, Artola MT, Cladera A, Tormo M, Bermúdez A, Vall-Llovera F, Martínez-Sánchez P, Amigo ML, Monsalvo S, Novo A, Cervera M, García-Guiñon A, Ciudad J, Cervera J, Hernández-Rivas JM, Granada I, Haferlach T, Orfao A, Solé F, Ribera JM. Adverse prognostic impact of complex karyotype (≥3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL). Leuk Res. 2021 Oct;109:106612. IF: 3.156.
Marcé S, Xicoy B, García O, Cabezón M, Estrada N, Vélez P, Boqué C, Sagüés M, Angona A, Teruel-Montoya R, Ferrer-Marín F, Amat P, Hernández-Boluda JC, Ibarra MM, Anguita E, Cortés M, Fernández-Ruiz A, Fontanals S, Zamora L, On Behalf Of The Grupo Español de Leucemia Mieloide Crónica Gelmc. Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib. J Clin Med. 2021 Jul 16;10(14):3146. IF: 4.242.
Martinez-Verbo L, Estrada N, Cabezón M, Palomo L, García O, Arnan M, Coll R, Xicoy B, Zamora L. Mutational profile and relative telomere length in Chronic Myelomonocytic Leukemia subgroups according to the 2016 World Health Organization classification. Leuk Res. 2021. 111p. 106726-106726. IF: 3,156.
Negre M,Balliu E, Ferran N, Velasco M, Roncero JM, Rubió A. Follicular dendritic cell tumor in the context of a Castleman disease in a patient with Diffuse Large B Cell Lymphoma: Diagnosis and follow-up with 18 F-FDG PET/CT. Rev. Esp. Med. Nucl. Imagen Mol. 2021. 40. (5):p. 322-324. IF:1,359.
Negre M, Balliu E, Rubió A, Peláez I, Mestre A, Roncero JM. Utility of the 18 F-FDG PET/CT in the diagnosis of the neurolymphomatosis: A case report. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2021. 40. (5):p. 328-331. IF:1,359.
Ocio EM, Montes-Gaisán C, Bustamante G, Garzón S, González E, Pérez E, Sirvent M, Arguiñano JM, González Y, Ríos R, de Miguel D, Grande M, Fernández A, Naves A, Rosiñol L. Clinical and Sociodemographic Characteristics of Patients With Relapsed and/or Refractory Multiple Myeloma and Their influence on Treatment in the Real-World Setting in Spain: The CharisMMa Study. Clin Lymphoma Myeloma Leuk. 2021 Oct 8:S2152-2650(21)02369-7. IF: 3.231.
Oñate G, Bataller A, Garrido A, Hoyos M, Arnan M, Vives S, Coll R, Tormo M, Sampol MA, Escoda L, Salamero O, Garcia A, Bargay J, Aljarilla A, Nomdedeu JF, Esteve J, Sierra J, Pratcorona M. Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1. Blood Adv. 2021 Sep 13:bloodadvances.2020004136. IF: 6.799.
Ribera J, Granada I, Morgades M, González T, Ciudad J, Such E, Calasanz MJ, Mercadal S, Coll R, González-Campos J, Tormo M, García-Cadenas I, Gil C, Cervera M, Barba P, Costa D, Ayala R, Bermúdez A, Orfao A, Ribera JM; Programa para el Tratamiento de Hemopatias Malignas (PETHEMA) Group (Spanish Society of Hematology, SEHH). Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable residual disease-oriented protocols. Br J Haematol. 2022 Feb;196(3):670-675. IF: 6,998.
Ribera JM, Morgades M, Ciudad J, Montesinos P, Esteve J, Genescà E, Barba P, Ribera J, García-Cadenas I, Moreno MJ, Martínez-Carballeira D, Torrent A, Martínez-Sánchez P, Monsalvo S, Gil C, Tormo M, Artola MT, Cervera M, González- Campos J, Rodríguez C, Bermúdez A, Novo A, Soria B, Coll R, Amigo ML, López- Martínez A, Fernández-Martín R, Serrano J, Mercadal S, Cladera A, Giménez-Conca A, Peñarrubia MJ, Abella E, Vall-Llovera F, Hernández-Rivas JM, Garcia-Guiñon A, Bergua JM, de Rueda B, Sánchez-Sánchez MJ, Serrano A, Calbacho M, Alonso N, Méndez-Sánchez JÁ, García-Boyero R, Olivares M, Barrena S, Zamora L, Granada I, Lhermitte L, Feliu E, Orfao A. Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome-negative adult lymphoblastic leukemia. Blood. 2021 Apr 8;137(14):1879-1894. IF 23.629.
Ribera JM, Morgades M, Coll R, Barba P, López-Lorenzo JL, Montesinos P, Foncillas MA, Cabrero M, Gómez-Centurión I, Morales MD, Varela MR, Herrera P, García-Cadenas I, Calbacho M, Torrent A, Maluquer C, Calabuig M, Garcia-Guiñon A, Bautista G, Llorente L, Gil C, Artola MT, González-Campos J, Fernández-Moreno A, Bárez A, Giménez-Pérez T, Bergua J, Sánchez-Sánchez MJ, Mateos MC, Piñana JL. Frequency, Clinical Characteristics and Outcome of Adults With Acute Lymphoblastic Leukemia and COVID 19 Infection in the First vs. Second Pandemic Wave in Spain. Clin Lymphoma Myeloma Leuk. 2021 Oct;21(10):e801-e809. IF: 3.231.
Ribera JM, Morgades M, Genescà E, Chapchap EC, Montesinos P, Acuña-Cruz E, Gil C, García-Cadenas I, Barba P, González-Campos J, Queipo de Llano MP, Torrent A, Ribera J, Granada I, Bernal T, Díaz-Beyá M, Amigo ML, Coll R, Tormo M, Vall- Llovera F, Gómez-Centurión I, Sánchez-Sánchez MJ, Soria B, Cladera A, Artola MT, Garcia-Guiñon A, Giménez-Conca A, Amador ML, Martínez-Sánchez P, Algarra JL, Vidal MJ, Alonso N, Maluquer C, Llorente L, García-Boyero R, Ciudad J, Feliu E, Orfao A; on behalf of the PETHEMA Group. Outcomes and prognostic factors of adults with refractory or relapsed T-cell acute lymphoblastic leukemia included in measurable residual disease-oriented trials. Hematol Oncol. 2021 Oct;39(4):529-538. IF: 5.271.
Villavicencio A, Solans M, Zacarías L, Vidal A, Puigdemont M, Roncero JM, Saez M, Marcos R. Comorbidities at Diagnosis, Survival, and Cause of Death in Patients with Chronic Lymphocytic Leukemia: A Population-Based Study. Int J Environ Res Public Health. 2021. 18. (2):701. IF: 3,390.
Publicacions 2022
Johana Díaz-Santa 1 , Rocío Rodríguez-Romanos 1 , Rosa Coll 1 , Gemma Osca 1 , Marta Pratcorona 2 , Marta González-Bártulos 1 , Ana Garrido 2 , Anna Angona 1 , Carme Talarn 3 , Mar Tormo 4 , Montserrat Arnan 5 , Susanna Vives 6 , Olga Salamero 7 , Esperanza Tuset 1 , Natàlia Lloveras 1 , Isabel Díez 1 , Lurdes Zamora 6 , Joan Bargay 8 , Antonia Sampol 9 , David Cruz 1 , Jordi Vila 1 , Marta Sitges 1 , Antoni Garcia 10 , Ferran Vall-Llovera 11 , Jordi Esteve 12 , Jorge Sierra 2 , David Gallardo 1 , “Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias” (CETLAM group) . 5'-nucleotidase, cytosolic II genotype, and clinical outcome in patients with acute myeloid leukemia with intermediate-risk cytogenetics Eur J Haematol . 2022 Dec;109(6):755-764.
JAlex Bataller 1 2 , Ana Garrido 2 3 , Francesca Guijarro 1 , Guadalupe Oñate 2 3 , Marina Diaz-Beyá 1 , Montserrat Arnan 4 , Mar Tormo 5 , Susana Vives 6 , María Paz Queipo de Llano 7 , Rosa Coll 8 , David Gallardo 8 , Ferran Vall-Llovera 9 , Lourdes Escoda 10 , Antonio Garcia-Guiñon 11 , Olga Salamero 12 , Antònia Sampol 13 , Brayan M Merchan 14 , Joan Bargay 15 , Sandra Castaño-Díez 1 , Daniel Esteban 1 , Aina Oliver-Caldés 1 , Andrea Rivero 1 , Pablo Mozas 1 , Mònica López-Guerra 16 17 , Marta Pratcorona 2 3 , Lurdes Zamora 2 6 , Dolors Costa 16 17 , Maria Rozman 16 , Josep F Nomdedéu 2 3 , Dolors Colomer 16 17 , Salut Brunet 2 3 , Jorge Sierra 2 3 , Jordi Esteve 1 2 European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol. Blood Adv.2022 Feb 22;6(4):1193-1206. doi: 10.1182/bloodadvances.2021005585.
Guadalupe Oñate 1 , Alex Bataller 2 , Ana Garrido 1 , Montserrat Hoyos 1 , Montserrat Arnan 3 , Susana Vives 4 , Rosa Coll 5 , Mar Tormo 6 , Antònia Sampol 7 , Lourdes Escoda 8 , Olga Salamero 9 , Antoni Garcia 10 , Joan Bargay 11 , Alba Aljarilla 1 , Josep F Nomdedeu 1 , Jordi Esteve 2 , Jorge Sierra 1 , Marta Pratcorona 1 Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1 Blood Adv 2022 Feb 8;6(3):882-890. doi: 10.1182/bloodadvances.2020004136.
David Llorens Poblador 1 , Marta Justicia Garriga 1 , Rosa Coll 2 Chemsex: on how to optimize access to postexposure HIV prophylaxis. Comment. Emergencias 2022 Apr;34(2):158.
[Article in English, Spanish]
Jordi Ribera 1 , Isabel Granada 1 , Mireia Morgades 1 , Teresa González 2 , Juana Ciudad 3 4 , Esperanza Such 5 , María-José Calasanz 6 , Santiago Mercadal 7 , Rosa Coll 8 , José González-Campos 9 , Mar Tormo 10 , Irene García-Cadenas 11 , Cristina Gil 12 , Marta Cervera 13 , Pere Barba 14 , Dolors Costa 15 , Rosa Ayala 16 , Arancha Bermúdez 17 , Alberto Orfao 3 4 , Josep-Maria Ribera 1 , Programa para el Tratamiento de Hemopatias Malignas (PETHEMA) Group (Spanish Society of Hematology, SEHH) Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable residual disease-oriented protocols Br J Haematol 2022 Feb;196(3):670-675. doi: 10.1111/bjh.17844. Epub 2021 Sep 21.
.Ricardo Sánchez 1 2 3 4 , Sara Dorado 5 6 , Yanira Ruíz-Heredia 5 , Alejandro Martín-Muñoz 5 , Juan Manuel Rosa-Rosa 7 8 , Jordi Ribera 9 , Olga García 9 , Ana Jimenez-Ubieto 10 8 , Gonzalo Carreño-Tarragona 10 8 , María Linares 8 11 , Laura Rufián 7 5 , Alexandra Juárez 10 5 , Jaime Carrillo 5 , María José Espino 10 , Mercedes Cáceres 10 , Sara Expósito 12 , Beatriz Cuevas 13 , Raúl Vanegas 14 , Luis Felipe Casado 15 , Anna Torrent 9 , Lurdes Zamora 9 , Santiago Mercadal 16 , Rosa Coll 17 , Marta Cervera 18 , Mireia Morgades 9 , José Ángel Hernández-Rivas 19 , Pilar Bravo 20 , Cristina Serí 21 , Eduardo Anguita 22 , Eva Barragán 23 , Claudia Sargas 23 , Francisca Ferrer-Marín 24 , Jorge Sánchez-Calero 25 , Julián Sevilla 26 , Elena Ruíz 27 , Lucía Villalón 28 , María Del Mar Herráez 29 , Rosalía Riaza 30 , Elena Magro 31 , Juan Luis Steegman 32 , Chongwu Wang 33 , Paula de Toledo 6 , Valentín García-Gutiérrez 34 , Rosa Ayala 10 7 8 35 , Josep-Maria Ribera 9 , Santiago Barrio # 10 7 8 5 , Joaquín Martínez-López # 36 37 38 39 Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA. Sci Rep.2022 Jul 29;12(1):13057.
A Triguero 1 , B Xicoy 2 , L Zamora 3 , M J Jiménez 2 , O García 4 , M Calabuig 5 , M Díaz-Beyá 6 , J Arzuaga 5 , F Ramos 5 , A Medina 5 , T Bernal 5 , C Talarn 5 , R Coll 5 , R Collado 5 , T Hua Chen 5 , J Borrás 5 , S Brunet 5 , I Marchante 5 , V Marco 5 , F López-Cadenas 5 , M Calbacho 5 , A Simiele 5 , M Cortés 5 , M T Cedena 5 , M Pedreño 5 , C Aguilar 5 , C Pedró 5 , M Fernández 5 , C Stoica 5 , J M Ribera 7 , G Sanz 5 Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic/myeloproliferative neoplasms criteria 2022 May;116:106836. doi: 10.1016/j.leukres Leuk Res 2022.106836. Epub 2022 Mar 26.
Jesus Fernandez-Sojo 1 2 , Joan Cid 3 , Carmen Azqueta 4 5 , Elena Valdivia 4 5 , Lluis Martorell 4 5 , Margarita Codinach 6 , Julia Marsal 7 , Alberto Mussetti 8 , Albert Esquirol 9 , Maria Trabazo 10 , Maria Isabel Benitez 11 , Christelle Ferra 12 , Maria Laura Fox 13 , Mónica Linares 5 14 , Eva Alonso 15 , Enric García-Rey 16 , Nadia García-Muñoz 17 , Laura Medina 18 , Nerea Castillo-Flores 19 , Ferran Vall-Llovera 20 , Antoni Garcia 21 , Asuncion Pinacho 22 , Carme Talarn 23 , Jose Garcia Arroba 24 , Rosa Coll 25 , Mireia Santos 26 , Oliver Valero 27 , Enric Carreras 28 , Miquel Lozano 3 , Sergio Querol 4 5Post thawing viable CD34+ Cells dose is a better predictor of clinical outcome in lymphoma patients undergoing autologous stem cell transplantation 2022 Aug;57(8):1341-1343. doi: 10.1038/s41409-022-01722-6. Epub. Bone Marrow Transplant 2022 May 25
Celia González-Gil 1 , Mireia Morgades 2 , Thaysa Lopes 1 , Francisco Fuster-Tormo 1 , Jesús García-Chica 1 , Ran Zhao 3 , Pau Montesinos 4 , Anna Torrent 2 , Marina Diaz-Beya 5 , Rosa Coll 6 , Lourdes Hermosín 7 , Santiago Mercadal 8 , José González-Campos 9 , Lurdes Zamora 2 , Teresa Artola 10 , Ferran Vall-Llovera 11 , Mar Tormo 12 , Cristina Gil-Cortés 13 , Pere Barba 14 , Andrés Novo 15 , Jordi Ribera 1 , Teresa Bernal 16 , Paula López De Ugarriza 16 , María-Paz Queipo 17 , Pilar Martínez-Sánchez 18 , Alicia Giménez 18 , Teresa González-Martínez 19 , Antonia Cladera 20 , José Cervera 4 , Rosa Fernández-Martín 21 , María Ángeles Ardaiz 22 , María Jesús Vidal 23 , Ángela Baena 24 , Nuria López-Bigas 25 , Anna Bigas 26 , Jaroslaw Maciejewski 27 , Alberto Orfao 28 , Josep Maria Ribera 29 , Eulalia Genescà 30 Genomics improves risk stratification of adults with T-cell acute lymphoblastic leukemia patients enrolled in measurable residual disease-oriented trials 2022 Nov 3. doi: 10.3324/haematol.Hematologica .2022.281196. Online ahead of print
Alex Bataller 1 2 , Ana Garrido 2 3 , Francesca Guijarro 1 , Guadalupe Oñate 2 3 , Marina Diaz-Beyá 1 , Montserrat Arnan 4 , Mar Tormo 5 , Susana Vives 6 , María Paz Queipo de Llano 7 , Rosa Coll 8 , David Gallardo 8 , Ferran Vall-Llovera 9 , Lourdes Escoda 10 , Antonio Garcia-Guiñon 11 , Olga Salamero 12 , Antònia Sampol 13 , Brayan M Merchan 14 , Joan Bargay 15 , Sandra Castaño-Díez 1 , Daniel Esteban 1 , Aina Oliver-Caldés 1 , Andrea Rivero 1 , Pablo Mozas 1 , Mònica López-Guerra 16 17 , Marta Pratcorona 2 3 , Lurdes Zamora 2 6 , Dolors Costa 16 17 , Maria Rozman 16 , Josep F Nomdedéu 2 3 , Dolors Colomer 16 17 , Salut Brunet 2 3 , Jorge Sierra 2 3 , Jordi Esteve 1 2 European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol Blood Adv . 2022 Feb 22;6(4):1193-1206. doi: 10.1182/bloodadvances.2021005585.
Nil Albiol 1 2 3 4 , Olga Aso 5 , Lucía Gómez-Pérez 5 , Mercè Triquell 5 , Nerea Roch 6 , Elisabeth Lázaro 5 , Albert Esquirol 5 7 8 9 , Iria González 5 , Joaquín López-Contreras 8 6 , Jorge Sierra 5 7 8 9 , Rodrigo Martino 5 7 8 9 , Irene García-Cadenas 10 11 12 13 Correction to: mRNA-1273 SARS-CoV-2 vaccine safety and COVID-19 risk perception in recently transplanted allogeneic hematopoietic stem cell transplant recipients. Published Erratum. Support Care Cancer. 2022 Nov 19;1. doi: 10.1007/s00520-022-07452-1. Online ahead of print.
Nil Albiol 1 2 3 4 , Olga Aso 5 , Lucía Gómez-Pérez 5 , Mercè Triquell 5 , Nerea Roch 6 , Elisabeth Lázaro 5 , Albert Esquirol 5 7 8 9 , Iria González 5 , Joaquín López-Contreras 8 6 , Jorge Sierra 5 7 8 9 , Rodrigo Martino 5 7 8 9 , Irene García-Cadenas 10 11 12 13 mRNA-1273 SARS-CoV-2 vaccine safety and COVID-19 risk perception in recently transplanted allogeneic hematopoietic stem cell transplant recipients. Support Care Cancer. Observational Study J. Thromb Thrombolysis. 2022 Sep 28;1-4. doi: 10.1007/s00520-022-07376-w. Online ahead of print
Mariana Corrochano 1 , René Acosta-Isaac 2 , Sergi Mojal 2 , Sara Miqueleiz 3 , Diana Rodriguez 3 , María Ángeles Quijada-Manuitt 4 , Edmundo Fraga 5 , Marta Castillo-Ocaña 4 , Kristopher Amaro-Hosey 4 , Nil Albiol 2 , José Manuel Soria 6 , Rosa Maria Antonijoan 4 7 , Joan Carles Souto 2 Impact of pre-admission antithrombotic therapy on disease severity and mortality in patients hospitalized for COVID-19 Observational Study J Thromb Thrombolysis 2022 Jan;53(1):96-102. doi: 10.1007/s11239-021-02507-2. Epub 2021 Jun 17
Luis-Esteban Tamariz-Amador 1 , Paula Rodríguez-Otero 2 , Ana Jiménez-Ubieto 3 , Laura Rosiñol 4 , Albert Oriol 5 , Rafael Ríos 6 , Anna Sureda 7 , Maria Jesus Blanchard 8 , Miguel Teodoro Hernández 9 , Valentin Cabañas Perianes 10 , Isidro Jarque 11 , Juan Bargay 12 , Mercedes Gironella 13 , Felipe De Arriba 14 , Luis Palomera 15 , Yolanda Gonzalez-Montes 16 , Josep M Martí 17 , Isabel Krsnik 18 , José María Arguiñano 19 , María Esther González 20 , Luis Felipe Casado 21 , Ana Pilar González-Rodriguez 22 , Lucía López-Anglada 4 , Noemi Puig 23 , Maria Teresa Cedena 3 , Bruno Paiva 24 , Maria-Victoria Mateos 23 , Jesús San-Miguel 24 , Juan-José Lahuerta 3 , Joan Bladé 4 , Iñaki F Trocóniz 25 Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma. Clin Lymphoma Myeloma Leuk 2022 Sep;22(9):e844-e852. doi: 10.1016/j.clml.2022.04.024. Epub 2022 May 5.
David F Moreno 1 , Victoria Clapés 2 , Juan Alfons Soler 3 , Yolanda González-Montes 4 , Mercedes Gironella 5 , Cristina Motlló 6 , Miquel Granell 7 , Eugenia Abella 8 , Marta García-Pintos 9 , Antoni García-Guiñón 10 , Elena Cabezudo 2 , Joan Bladé 1 , Laura Rosiñol 11 Real-World Evidence of Daratumumab Monotherapy in Relapsed/Refractory Multiple Myeloma Patients and Efficacy on Soft-Tissue Plasmacytomas Clin Lymphoma Myeloma Leuk .2022 Aug;22(8):635-642. doi: 10.1016/j.clml.2022.04.014. Epub 2022 Apr 17
Laura Vilorio-Marqués 1 , Christelle Castañón Fernández 1 , Elvira Mora 2 , Lorena Gutiérrez 3 , Beatriz Rey Bua 4 , Maria José Jiménez Lorenzo 5 , Marina Díaz Beya 6 , Miriam Vara Pampliega 7 , Antonieta Molero 8 , Joaquín Sánchez-García 9 , Marisa Calabuig 10 , Maria Teresa Cedena 11 , Tzu Chen-Liang 12 , Johana Alejandra Díaz Santa 13 , Irene Padilla 14 , Francisca Hernández 15 , Rosana Díez 16 , Pedro Asensi 2 , Blanca Xicoy 5 , Guillermo Sanz 2 , David Valcárcel 8 , María Diez-Campelo 4 , Teresa Bernal Relevance of infections on the outcomes of patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia treated with hypomethylating agents: a cohort study from the GESMD Ther Adv Hematol .2022 Sep 29;13:20406207221127547. doi: 10.1177/20406207221127547. eCollection 2022.
Barbui T, Iurlo A, Masciulli A, Carobbio A, Ghirardi A, Carioli G, Sobas MA, Elli EM, Rumi E, De Stefano V, Lunghi F, Marchetti M, Daffini R, Gasior Kabat M, Cuevas B, Fox ML, Andrade-Campos MM, Palandri F, Guglielmelli P, Benevolo G, Harrison C, Foncillas MA, Bonifacio M, Alvarez-Larran A, Kiladjian JJ, Bolaños Calderón E, Patriarca A, Quiroz Cervantes K, Griessammer M, Garcia-Gutierrez V, Marin Sanchez A, Magro Mazo E, Ruggeri M, Hernandez-Boluda JC, Osorio S, Carreno-Tarragona G, Sagues Serrano M, Kusec R, Navas Elorza B, Angona A, Xicoy Cirici B, Lopez Abadia E, Koschmieder S, Cattaneo D, Bucelli C, Cichocka E, Masternak Kulikowska de Nałęcz A, Cavalca F, Borsani O, Betti S, Benajiba L, Bellini M, Curto-Garcia N, Rambaldi A, Vannucchi AM. Second versus first wave of COVID-19 in patients with MPN. Leukemia. 2022 Mar;36(3):897-900
Alvarez-Larrán A, Garrote M, Ferrer-Marín F, Pérez-Encinas M, Mata-Vazquez MI, Bellosillo B, Arellano-Rodrigo E, Gómez M, García R, García-Gutiérrez V, Gasior M, Cuevas B, Angona A, Gómez-Casares MT, Martínez CM, Magro E, Ayala R, Del Orbe-Barreto R, Pérez-López R, Fox ML, Raya JM, Guerrero L, García-Hernández C, Caballero G, Murillo I, Xicoy B, Ramírez MJ, Carreño-Tarragona G, Hernández-Boluda JC, Pereira A; MPN Spanish Group (Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas). Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea. Cancer. 2022 Jul 1;128(13):2441-2448.
García-Fortes M, Hernández-Boluda JC, Álvarez-Larrán A, Raya JM, Angona A, Estrada N, Fox L, Cuevas B, García-Hernández MC, Gómez-Casares MT, Ferrer-Marín F, Saavedra S, Cervantes F, García-Delgado R, On Behalf Of The Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas Gemfin. Impact of Individual Comorbidities on Survival of Patients with Myelofibrosis. Cancers (Basel). 2022 May 9;14(9):2331. doi: 10.3390/cancers14092331.
Hernández-Boluda JC, Pastor-Galán I, Arellano-Rodrigo E, Raya JM, Pérez-Encinas M, Ayala R, Ferrer-Marín F, Velez P, Mora E, Fox ML, Hernández-Rivas JM, Xicoy B, Mata-Vázquez MI, García-Fortes M, Pérez-López R, Angona A, Cuevas B, Senín A, Ramírez MJ, Ramírez-Payer A, Gómez-Casares MT, Martínez-Valverde C, Magro E, Steegmann JL, Durán MA, García-Hernández C, Gasior M, de Villambrosia SG, Alvarez-Larrán A, Pereira A; Spanish MPN Group (GEMFIN). Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis. Br J Haematol. 2022 Sep 12. doi: 10.1111/bjh.18440
Barbui T, Carobbio A, Ghirardi A, Iurlo A, Sobas MA, Elli EM, Rumi E, De Stefano V, Lunghi F, Marchetti M, Daffini R, Gasior Kabat M, Cuevas B, Fox ML, Andrade-Campos MM, Palandri F, Guglielmelli P, Benevolo G, Harrison C, Foncillas MA, Bonifacio M, Alvarez-Larran A, Kiladjian JJ, Bolaños Calderón E, Patriarca A, Quiroz Cervantes K, Griesshammer M, Garcia-Gutierrez V, Marin Sanchez A, Magro Mazo E, Carli G, Hernandez-Boluda JC, Osorio S, Carreno-Tarragona G, Sagues Serrano M, Kusec R, Navas Elorza B, Angona A, Xicoy Cirici B, Lopez Abadia E, Koschmieder S, Cattaneo D, Bucelli C, Cichocka E, de Nałęcz AK, Cavalca F, Borsani O, Betti S, Bellini M, Curto-Garcia N, Rambaldi A, Vannucchi AM. Determinants of early triage for hospitalization in myeloproliferative neoplasm (MPN) patients with COVID-19. Am J Hematol 2022 Sep 16. doi: 10.1002/ajh.26732.
Triguero A, Pedraza A, Pérez-Encinas M, Mata-Vázquez MI, Vélez P, Fox L, Gómez-Calafat M, García-Delgado R, Gasior M, Ferrer-Marín F, García-Gutiérrez V, Angona A, Gómez-Casares MT, Cuevas B, Martínez C, Pérez R, Raya JM, Guerrero L, Murillo I, Bellosillo B, Hernández-Boluda JC, Sanz C, Álvarez-Larrán A; On behalf of the MPN Spanish Group (GEMFIN). Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera. Ann Hematol. 2022 Oct;101(10):2231-2239.
Carmen Martínez 1 , Manuel Espeso de Haro 2 , Samuel Romero 3 , Antonio Gutiérrez 4 , Eva Domingo-Domènech 5 , Ana P González-Rodríguez 6 , Izaskun Zeberio 7 , María Paz Martínez-Badas 8 , Antonia Rodríguez-Izquierdo 9 , Cecilia Carpio 10 , Mariana Bastos-Oreiro 11 , José Ángel Hernández-Rivas 12 , Rolando Vallansot 13 , Nicholas Kelleher 14 , Francisco J Díaz-Gálvez 15 , Tamara Torrado 16 , Arturo Pereira 17 , Ramón García-Sanz 18 , Grupo Español de Linfoma y Trasplante de Médula Ósea (GELTAMO) y Grupo Español de Trasplante (GETH) Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma 2022 Nov 12. doi: 10.1007/s00277-022-05011-6. Online ahead of print.
Blanca Gonzalez-Farre 1 2 3 , Joan E Ramis-Zaldivar 2 3 , Natalia Castrejón de Anta 1 2 , Alfredo Rivas-Delgado 2 4 , Ferran Nadeu 2 3 , Julia Salmeron-Villalobos 2 3 , Anna Enjuanes 2 , Kennosuke Karube 5 , Olga Balagué 1 2 3 , Francesc Cobo 6 , Nicholas Kelleher 7 , Ingrid Victoria 1 , Luis Veloza 1 8 , Cristina Teixido 1 2 , Eva Giné 2 4 3 , Mónica Lopez-Guerra 1 2 3 , Leticia Quintanilla-Martinez 9 , Armando Lopez-Guillermo 2 4 3 , Itziar Salaverria 2 3 , Elias Campo 1 2 3 Intravascular Large B-Cell Lymphoma Genomic Profile Is Characterized by Alterations in Genes Regulating NF-κB and Immune Checkpoints Ann Hematol . 2022 Oct 12. doi: 10.1097/PAS.0000000000001978. Online ahead of print.
Paula Muñiz 1 2 , Cristina Andrés-Zayas 2 3 , Diego Carbonell 1 2 , María Chicano 1 2 , Rebeca Bailén 1 2 , Gillen Oarbeascoa 1 2 , Julia Suárez-González 2 3 , Ignacio Gómez Centurión 1 2 , Nieves Dorado 1 2 , David Gallardo 4 , Javier Anguita 1 2 , Mi Kwon 1 2 , Jose L Díez-Martín 1 2 5 , Carolina Martínez-Laperche 1 2 , Ismael Buño Association between gene polymorphisms in the cyclophosphamide metabolism pathway with complications after haploidentical hematopoietic stem cell transplantation Am J Surg Pathol.2022 Sep 23;13:1002959. doi: 10.3389/fimmu.2022.1002959. eCollection 2022.
